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ABSTRACT 
Aim: Myocardial Na+/H+ exchanger-1 (NHE-1) hyperactivity and oxidative stress are 
interrelated phenomena playing pivotal roles in the development of pathological 
cardiac hypertrophy and heart failure. Exercise training is effective to convert 
pathological into physiological hypertrophy in the spontaneously hypertensive rats 
(SHR) and IGF-1 –key humoral mediator of exercise training- inhibits myocardial 
NHE-1, at least in normotensive rats. Therefore, we hypothesize that IGF-1 by 
hampering NHE-1 hyperactivity and oxidative stress should exert a cardioprotective 
effect in the SHR. Methods: NHE-1 activity [proton efflux (JH+) mmol L min-1], 
expression and phosphorylation; H2O2 production; superoxide dismutase (SOD) 
activity; contractility and calcium transients were measured in SHR  hearts in the 
presence/absence of IGF-1. Results: IGF-1 significantly decreased NHE-1 activity 
(JH+ at pHi 6.95: 1.39±0.32, n=9 vs. C 3.27±0.3, n=20, p <0.05); effect prevented by 
AG1024, an antagonist of IGF-1 receptor (2.7±0.4, n=7); by the PI3K inhibitor 
wortmannin (3.14±0.41 n=7); and the AKT inhibitor MK2206 (3.37±0.43, n=14). 
Moreover, IGF-1 exerted an antioxidant effect revealed by a significant reduction in 
H2O2 production accompanied by an increase in SOD activity. In addition, IGF-1 
improved cardiomyocyte contractility as evidenced by an increase in sarcomere 
shortening and a decrease in the relaxation constant, underlined by an increase in 
the amplitude and rate of decay of the calcium transients. 
Conclusions: IGF-1 exerts a cardioprotective role on the hypertrophied hearts of the 
SHR, in which the inhibition of NHE-1 hyperactivity, as well as the positive inotropic 
and antioxidant effects, emerge as key players.  
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1. INTRODUCTION 
There is strong evidence supporting that the Na+/H+ exchanger-1 (NHE-1) is 
critically involved in cardiac diseases, especially in pathological cardiac hypertrophy 
and its evolution to heart failure.1, 2 The NHE-1 catalyzes the exchange of 
intracellular H+ for extracellular Na+. Its functional up-regulation is sufficient to induce 
pathological cardiac hypertrophy while its specific inhibition represents an efficient 
approach to induce cardiac hypertrophy prevention or regression.2-4 
The spontaneously hypertensive rats (SHR) are a well-known model of essential 
hypertension that results in pathological cardiac hypertrophy. We and others have 
demonstrated that the NHE-1 is hyperactive in the hypertrophied myocardium of 
these rats.5, 6 Myocardial stretch due to hemodynamic overload stimulates an 
autocrine/paracrine mechanism that involves the activation of the ERK/p90RSK 
pathway conducting to NHE-1 phosphorylation and hyperactivity.2, 7 The resulting 
increase in intracellular Na+ content decreases the forward and facilitates the reverse 
mode of operation of the Na+/Ca2+ exchanger, ultimately promoting the activation of 
calcineurin. The latter is a prohypertrophic phosphatase critical for pathological 
cardiac hypertrophy development. Interestingly, in the SHR we have demonstrated 
that sustained exercise training is capable of transforming the hypertension-induced 
pathological cardiac hypertrophy into a physiological one, improving not only 
myocardial structure but also cardiac function at the time that calcineurin activity is 
normalized.8  
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The physiologic adaptation to exercise involves the production and release of 
several growth factors and other humoral mediators among which, the insulin-like 
growth factor 1 (IGF-1) seems to be the most relevant. It has been reported that 
exercise training rises the levels of IGF-1 in athletes as well as in animal models. 9-11 
The importance of the IGF-1 in the development of physiological cardiac hypertrophy 
has been also confirmed by evidence arose from transgenic mice overexpressing the 
IGF1 receptor (IGF-1R) in the heart or, on the contrary, with cardiomyocyte-specific 
knockout of this receptor.12, 13 The activation of this membrane receptor stimulates at 
least to main signalling cascades: the PI3K/AKT pathway, the most important in 
exercise-induced physiological hypertrophy development, and the ERK pathway.14 
Accordingly, physiological cardiac hypertrophy12, 15, 16 can be eluded by 
pharmacological or genetic inhibition of PI3K or AKT1, while the opposite occurs 
when a constitutively active PI3K is overexpressed in the heart. 12, 15, 16 17 With 
respect to the contractile adaptation, we recently reported in mice cardiomyocytes 
that IGF-1 induces a positive inotropic and lusitropic effect that was mediated by the 
activation of the calcium-calmodulin kinase II (CaMKII) and the phosphorylation of 
phospholamban (PLN).18  
Interestingly, we have recently reported that IGF-1, through an AKT-dependent 
mechanism, exerts an inhibitory action upon the NHE-1 in cardiomyocytes from 
normotensive rats (Wistar).19 Moreover, in cardiomyocytes from these rats after 
being subjected to a swimming routine, and therefore hemodynamic overload, we did 
not detect calcineurin/NFAT activation, suggesting that NHE-1 hyperactivity, 
characteristic of pathological hypertrophy, was prevented in this model of cardiac 
hypertrophy.19  
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Large amount of evidence support the idea that reactive oxygen species (ROS) play 
a key role in the development of pathological cardiac hypertrophy and its progression 
to failure.20, 21 However, the underlying molecular mechanism involved remains to be 
elucidated. Mitochondria are the main source of ROS production, while the NADPH 
oxidase, xanthine oxidase and the uncoupled nitric oxide synthase are the main 
extra mitochondrial sources. The SHR myocardium is characterized by augmented 
oxidative damage compared to the myocardium of normotensive rats, evidenced by 
an increase in lipid peroxidation (TBARS), protein nitration and NADPH oxidase 
activity.22 Interestingly, we have previously demonstrated that pharmacologic 
inhibition of the NHE-1 was able to decrease myocardial ROS production in cat 
myocardium by a direct mitochondrial action.23  
Based on this evidence we hypothesise that IGF-1, through impeding NHE-1 
hyperactivity and improving redox balance, would be a key player in the 
cardioprotective effect of training upon the hypertrophied myocardium of the SHR. A 
main component of this effect would be an AKT-dependent inhibitory 
phosphorylation of the NHE-1. 
2. RESULTS 
The activity of the NHE-1 was explored in isolated cardiomyocytes from SHR and 
normotensive Wistar rats. As expected, the recovery from an induced intracellular 
acidosis was significantly faster in SHR than in Wistar cardiomyocytes, confirming 
that this ion exchanger is hyperactive in the hypertrophied myocardium of the SHR 
(Figure 1A). Since the exchanger hyperactivity could be the result of increased 
NHE-1 expression and/or a post-translational modification of the protein, both 
possibilities were evaluated. We found that the NHE-1 was similarly expressed in the 
hypertrophied myocardium of the SHR and the normotrophic one of the Wistar rats 
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(Figure 1B); however, we detected a significant increase in the phosphorylation 
state of the cytosolic tail residue Ser703, a modification widely recognized to 
stimulate NHE-1 activity (Figure 1C, left panel).24, 25 Since it has also been 
described an inhibitory AKT-dependent phosphorylation of the exchanger at the 
residue Ser648,19, 26 we explore this site too. As it can be appreciated in Figure 1C, 
right panel no significant differences were observed at this point. In line with these 
data, a greater activation of the ERK1/2 pathway, responsible for Ser703 
phosphorylation, was observed in the myocardium of SHR compared to Wistar rats. 
On the contrary, no difference was detected in the activation of AKT (Figure 1D).  
Since our aim was to reveal in hypertrophied hearts a putative effect of IGF-1 on the 
NHE-1, we explore the exchanger activity in isolated SHR cardiomyocytes after 24 
hs. of culture with/without IGF-1. In agreement with our previous report in non-
hypertrophied cardiomyocytes,19 a significant reduction in NHE-1 dependent proton 
efflux was observed in the SHR cardiomyocytes exposed to IGF-1. In order to get 
insight into the molecular mechanism involved, NHE-1 activity was measured in the 
presence of different inhibitors. The effect of IGF-1 was avoided not only by AG1024, 
an antagonist of the IGF-1R, but also by preventing PI3K or AKT activation with 
wortmannin and MK2206, respectively (Figure 2A-B). None of these inhibitors exert 
a significant effect on NHE-1 activity in the absence of IGF-1 (JH+ at pHi 6.95: 
4.293±1.598 n=5; 5.339±1.058 n=9; 3.685±1.393 n=7; and 2.991±0.574 n=7 for 
AG1024, wortmannin, MK2206 and DMSO respectively). On the other hand, the 
decrease in the activity of the NHE-1 induced by IGF-1 could not be attributed to a 
modification in either NHE-1 expression or the buffer capacity as shown in Figure 
2C-D, respectively. Moreover, the values of pHi at the maximal acidification reached 
were not different among the experimental groups (control: 6.925±0.024; IGF-1: 
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6.937±0.016; IGF-1+AG1024: 6.880±0.035; IGF-1+ wortmannin: 6.884±0.022; IGF-
1+MK2206: 6.893±0.038).   
These functional data was supported by the results obtained when exploring the 
consequences of IGF-1 stimulation on IGF-1R, AKT and ERK1/2-p90RSK 
phosphorylation state. IGF-1 significantly increased the phosphorylation of all these 
signaling molecules (Figure 3A-D). Importantly, these results were in agreement 
with the phosphorylation measured at the cytosolic tail of the exchanger, where an 
increase in the AKT-dependent inhibitory site (Ser648) was detected with no 
difference at the stimulatory residue Ser703, target of the ERK1/2-p90RSK pathway 
(Figure 3E).  
Previous results of our group demonstrated that chronic swimming has the ability to 
improve cardiac contractile function in the SHR,8 therefore in a new set of 
experiments we explored the consequences of IGF-1 on contractility. By measuring 
sarcomere length in SHR isolated ventricular myocytes we were able to detect a 
positive inotropic effect of IGF-1 (Figure 4A-B). Interestingly, IGF-1 also seemed to 
improve cardiomyocyte relaxation as revealed by a decrease in the relaxation time 
constant, Tau (Figure 4C). These effects were prevented by the blockade of the 
IGF-1R with AG1024 and by preventing AKT activation with MK2206. In order to gain 
further insight into the mechanism underlying the positive inotropic/lusitropic effect of 
IGF-1, of IGF-1, calcium transients were recorded in isolated cardiomyocytes. As 
shown in Figure 5A-C and in agreement with previous findings of our group 18, IGF-1 
significantly increased the amplitude and rate of decay of the calcium transients. 
Based on these results,18 we next explored the involvement of CaMKII. To this aim, 
we measured the phosphorylation level of this kinase as well as of residue threonine 
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17 (Thr17) of PLN, its well-recognized downstream target. We were able to detect a 
significant increase in in the phosphorylation of both proteins in the presence of IGF-
1 that was efficiently prevented by antagonizing the IGF-1R with AG.  On the 
contrary, we did not detect a significant difference in the phosphorylation of the PKA 
site on PLN (Ser16) (Figure 5D). 
Oxidative stress is another distinctive feature of pathological cardiac hypertrophy. 
Therefore, we investigated the effect of IGF-1 upon SHR myocardial H2O2 
accumulation and the activity of the antioxidant enzymes SOD. IGF-1 significantly 
attenuated H2O2 fluorescence (Figure 6A-B) while it increased the activity of 
myocardial SOD by an AKT-dependent mechanism (Figure 6C-D). Neither AG1024 
nor MK2206 significantly influenced SOD activity in the absence of IGF-1 (27±2 n=4 
and 25±2 n=4, respectively). 
3. DISCUSSION 
The main contribution of the present work is the evidence provided about the 
subcellular mechanisms underlying the beneficial effects of IGF-1 on the 
hypertrophied myocardium of the SHR. Herein, we demonstrated that IGF-1: 1- 
prevents myocardial NHE-1 hyperactivity through an AKT-dependent inhibitory 
phosphorylation of the cytosolic tail of the exchanger; 2- improves sarcomere 
shortening and relaxation  by increasing the amplitude and the rate of decay of 
calcium transients; and 3- improves redox state by decreasing H2O2 accumulation 
and augmenting SOD activity.  
In 2009, we reported that a 60 day period of swimming training was able to 
convert SHR pathological cardiac hypertrophy into a physiological phenotype, 
improving not only myocardial structure but also cardiac function.8 However, at that 
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moment we did not explore the underling mechanism involved in the beneficial 
cardiac consequences of exercise. Based on our present results, it is tempting to 
speculate that the events schematized in Figure 7 may also explain the 
cardioprotection observed in trained SHR8 through the release of IGF-1. 
IGF-1 is a 70 amino acid growth factor produced by most, if not all, body tissues 
including cardiomyocytes. Cardiac formation of IGF-1 –that is higher in athletes than 
in control subjects- seems to be the main player in physiological cardiac 
hypertrophy.10 Apart from its role in stimulating cardiomyocyte growth, we have 
recently demonstrated that IGF-1 can inhibit cardiac NHE-1 hyperactivity in normal 
hearts.19 This is crucial since it has been widely demonstrated that not only chronic 
NHE-1 hyperactivity plays a key role in pathological cardiac hypertrophy 
development but also its specific inhibition is sufficient to induce hypertrophy 
regression.4, 24, 27-31  The main mechanism involved would be the cytoplasmic sodium 
overload that reduces forward and favors reverse mode of the sarcoplasmic 
Na+/Ca2+ exchanger increasing cytoplasmic calcium and as a consequence 
calcineurin activation, among other prohypertrophic molecules. 29 Another important 
consequence of NHE-1 hyperactivity in the setup of pathologic cardiac hypertrophy 
and heart failure would be the decrease in mitochondrial calcium (again due to 
cytoplasmic sodium overload) that favors oxidative stress and impairs ATP 
synthesis.32 On the other hand, NHE-1 acute activation in response to intracellular 
acidosis is crucial in order to keep intracellular pH in the physiologic range, even 
more during high metabolic states such as exercise. In this sense, it is important to 
highlight that under physiological hemodynamic overload, i.e. endurance training, 
despite the myocardium is stretched, NHE-1 is not hyperactive but preserves its 
function to participate in steady-state intracellular pH regulation.19 Interestingly, in the 
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present work we demonstrate that IGF-1 is also capable of impeding NHE-1 
hyperactivity in the hypertrophied cardiomyocytes of the SHR. This effect depends 
on the activation of the IGF-1R and the PI-3K/AKT pathway leading to the inhibitory 
phosphorylation of the residue Ser648 in the regulatory domain of the exchanger.  
Based on our previous results unveiling an improvement in cardiac function in the 
swimming-trained SHR8 we evaluated the acute effect of IGF-1 upon contractility in 
hypertrophied SHR isolated cardiomyocytes. We were able to identify a significant 
improvement in contraction as well as in relaxation. This data is in agreement with 
similar findings already reported for both normal and failing cardiomyocytes,18, 33-36 
but are in conflict with the results of Ren et al.37 These last authors were not able to 
detect a positive inotropic effect of IGF-1 in SHR cardiomyocyte, although they did it 
in cardiomyocytes from normotensive rats, suggesting the existence of an IGF-1 
resistant state in the SHR hearts. However, it has been repeatedly reported the up-
regulation of the IGF-1R, both at the mRNA and protein level in various models of 
hypertension, including human essential hypertension.38-40 
With respect to the mechanism involved in the acute positive inotropic/lusitropic 
effect of IGF-1, there are some results from others and our own group already 
published, although contradictory. It has been proposed both an increase in calcium 
availability,18, 35 as well as the opposite situation: conserved calcium transients with 
improved myofilament sensitivity.41 Under the experimental conditions of our work, 
we were able to detect an increase in calcium transient amplitude and rate of decay, 
probably due to an improvement in SERCA 2a function secondary to the CaMKII-
phosphorylation of PLN. In the setup of chronic treatment with IGF-1 the increases in 
contraction and relaxation were attributed to an up-regulation of SERCA 2a 
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expression.36 This cannot be the case in our experiments, due to the short incubation 
time with IGF-1 (15 min) used.  
Common to cardiovascular diseases, including hypertensive cardiac hypertrophy, is 
increased oxidant stress, characterized by the spatio-temporal imbalance between 
the production of ROS and/or reactive nitrogen species and the detoxification 
through enzymatic and non-enzymatic systems. Despite the fact that limited levels of 
these molecules are necessary for several physiological processes,42, 43 studies 
using cell culture and experimental animal models clearly support the role of oxidant 
stress in the onset and progression of cardiac diseases. In the present work, and in 
agreement with previous reports (for review see 44), we were able to detect an 
antioxidant effect of IGF-1 evidenced by a decrease in cardiac H2O2 accumulation 
and a higher SOD activity. Further research will be necessary to elucidate the 
subcellular mechanism involved in this antioxidant effect of IGF-1. Regarding to SOD 
activity, an AKT-dependent post-translational modification of the enzyme seems to 
play a key role under the experimental conditions assayed by us. Interestingly, by 
using the group-based phosphorylation predicting and scoring method we found 
potential AKT phosphorylation consensus sites in SOD. 45 In line with our results are 
those obtained by Borges et al. who found that exercise training increases SOD 
activity by a post-translational mechanism in hearts from exercised Wistar rats.46 
Another mechanism that could be probably contributing to the decrease in oxidative 
stress is the prevention of intracellular sodium overload by the inhibition of NHE-1 
hyperactivity preserving mitochondrial calcium, as it has been recently reported by 
Baartscheer and colleagues.32 The latter is considered to be an important activator of 
ATP synthesis and of the antioxidant enzymatic network.47, 48 
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Several potential limitations should be acknowledged in this study. First, the 
concentration used of IGF-1 used appears to be relatively high compared to the 
plasma concentration (15-30 ng ml-1). However, the myocardium itself produces 
IGF-1 possibly leading to higher local concentrations. Second, we did not explore the 
exact mechanism responsible for the reduction in H2O2. Based on previous results 
from our group, in which NHE-1 inhibition reduced mitochondrial ROS production,23 
we think this as the most probable explanation. However, future experiments will be 
necessary to elucidate this point. Last but not least, further insight will be necessary 
to clarify the intracellular events contributing to the positive inotropic/lusitropic effect 
of IGF-1.  
4. MATERIAL AND METHODS 
Male SHRs at 4 months of age (body weight: 300–400 g) were anesthetized by 
intraperitoneal injection of ketamine (50 mg kg-1 of body weight) diazepam (2.5 mg 
kg-1 of body weight) and hearts rapidly excised when plane 3 of phase III of 
anaesthesia was reached.  
All procedures followed during this investigation conform to the to the 'European 
Convention for the Protection of Vertebrate Animals used for Experimental and other 
Scientific Purposes' (Council of Europe No 123, Strasbourg 1985) and the 
experimental protocol was approved by the Animal Welfare Committee of La Plata 
School of Medicine.  
4.1 Heart perfusion, cell isolation and culture:  
Hearts were retrograde perfused with a CO2/HCO3−-buffered solution equilibrated 
with 5% CO2–95% O2 at 37 °C (pH ∼7.40), during 15 min under the presence or 
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absence of IGF-1, as previously described.19 Pharmacologic inhibitors were added 5 
minutes before IGF-1, when indicated.  
Rat ventricular myocytes were isolated from hearts mounted in a Langendorff 
apparatus and then suspended in supplemented medium to attach to glass 
coverslips pretreated with laminin as previously described. 19  Unattached myocytes 
were removed by gently changing the medium. The new medium was the same than 
the previous one except for being serum deprived, and, when corresponding, 
supplemented with 10 nmol L-1 IGF-1. The different antagonists used were added to 
the serum-deprived medium 10 minutes before IGF-1. Cardiomyocytes were kept in 
culture for 24 h.  
4.2 NHE-1 Activity 
Intracellular pH (pHi) was recorded in single myocytes maintained in HCO3- free 
solution following the previously described BCECF epifluorescence technique.19, 49 
The ammonium pre-pulse (20 mmol L-1 NH4Cl for 3 min)-induced acid load method 
was used to calculate proton efflux (JH+) in order to evaluate NHE-1 activity following 
a protocol already described.19 
4.3 Real time RT-PCR  
NHE-1 mRNA expression normalized to GAPDH was measured by real-time RT-
PCR in cultured cardiac myocytes following a procedure previously described.50 The 
following primers were used: 5’-GGGTGTGAACCACGAGAAAT-3’ (forward) and 5’-
CCACAGTCTTCTGAGTGGCA-3’ (reverse) for GAPDH; 5’- 
TCACCACAGCTCCATCAGAG-3’ (forward) and 5’- GATCTCGAAGGGTGTCCGTA-
3’ (reverse). 
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4.4 Western Blotting  
Myocardial samples from the left ventricles were homogenized according to a 
procedure previously described.19 For the immunodetection, the following specific 
antibodies were used: anti phospho-ERK1/2 (Santa Cruz Biotechnology, sc-16982), 
anti phospho-AKT (Cell Signaling, 4060S), anti phospho-p90RSK (Cell Signaling 
#9341), anti NHE-1 (Santa Cruz Biotechnology sc-28758), anti phospho-Thr286-
CaMKII (P-CaMKII, 1:1000; Abcam), anti phospho-Thr17-PLN (2:500; Badrilla) and 
anti phospho-Ser16-PLN (2:500; Millipore). Phosphorylation at Ser703 or Ser648 
was estimated in immunoprecipitated NHE-1 incubated with anti-P-14-3-3 binding 
motif antibody (Cell Signaling, #9601) or anti-P-AKT substrate (Cell Signaling, 
#10001S) as previously described.24, 26 IGF-1R phosphorylation was determined in 
immunoprecipitated samples as previously described.51 The detection of GAPDH 
(Millipore MAB374) was used as a loading control for the immunoblots except when 
the phosphorylation of NHE-1 or IGF-1R was being evaluated in immunoprecipitated 
samples. In these particular cases, the total amount of each specific protein 
immunoprecipitated (phosphorylated and unphosphorylated) was use as the loading 
control. The secondary antibodies used were peroxidase-conjugated anti-rabbit 
(NA934, GE Healthcare Life Sciences), anti-mouse (NA931, GE Healthcare Life 
Sciences) or anti-goat IgG (sc-2004). Bands were visualized and analyzed as 
previously.19   
4.5 Contractility/Relaxation and Calcium transients 
The effect of IGF-1 on contractility was explored in ventricular myocytes superfused 
with a solution containing 1 mmol L-1 CaCl2, pH 7.4 with continuous bubbling with 
1% CO2 and 99% O2  at 30 °C in an inverted microscope (Nikon TE 2000-U). 
Myocytes were stimulated via two-platinum electrodes on either side of the bath at 
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0.5 Hz. The myocytes were observed using a video-camera connected to the 
microscope and sarcomere length (SL) was recorded by specific software (ION 
WIZARD analysis software). Contractility was measured in a limited region of the 
myocyte and the software estimated the most frequent SL in that region using fast 
Fourier transforms analysis (Ion Optix, Milton, MA). Time constant of twitch decay 
(tau) was measured as an indication of relaxation. Myocytes were allowed to 
contract over 5 minutes to ensure steady state before superfusion with IGF-1.  
A previously described protocol was follow to measure intracellular calcium 
measurements in isolated cardiomyocytes loaded with 10 μmol/L Fura-2 AM 
(Molecular probes).18 When corresponding, inhibitors were applied to the cells 5 
minutes before IGF-1 addition. Results were expressed as a percentage of time cero 
(immediately before IGF-1 addition).  
4.6 ROS production 
ROS production was measured in freshly isolated cardiomyocytes loaded with 10 
μmol L-1 5- (and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl 
ester (CM-H2DCFDA, Invitrogen) as previously reported.18 Briefly, cardiomyocytes 
were excited at 495 nm and emission spectra was acquired through a 510 nm filter 
with a Nikon camera attached to an inverted Zeiss LSM 410 microscope. During 20 
min, photographs were taken every 30 seconds in the different experimental groups. 
When indicated, the inhibitors were administrated 5 min before IGF-1. Results were 
analyzed with Image J software and expressed as the ratio between the slope 
after/before IGF-1. 
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4.7 Superoxide dismutase (SOD)activity  
SOD activity was determined by inhibition of formazan production (produced by 
nitroblue tetrazolium [NBT] reduction by superoxide anion) at pH 10.2 and 25°C as 
described previously.22 The reaction was started by the addition of xanthine oxidase, 
and then the absorbance at 560 nm was read every 10 seconds for 120 seconds. 
One unit of SOD was defined as the amount of enzymatic protein required to inhibit 
50% of NBT reduction. 
4.8. Chemicals  
All drugs used in the present study were analytical reagent. IGF-1 (10 nmol L-1): 
recombinant mouse insulin like growth factor -1 from Gibco by Life Technologies 
(Cat # PMG0075); AG1024 (100 nmol L-1): IGF-1R antagonist from Santa Cruz 
Biotechnology (Cat # sc-205907); MK2206 (500 nmol L-1): AKT inhibitor from 
Selleck Chemicals (Cat # S1078); wortmannin (100 nmol L-1): PI3K inhibitor from 
Sigma Argentina (Cat # W1628). Wortmannin, MK2206 and AG1024 were diluted in 
DMSO (final concentration 0.01%).  
4.9. Statistics  
Results are expressed as mean ± SEM. The Student t test, 1-way ANOVA followed 
by the Student-Newman-Keuls test or two-way ANOVA were used when 
corresponding. Significance level was set at p < 0.05.  
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LEGENDS TO FIGURES 
Figure 1. The NHE-1 is hyperactive in the myocardium of the SHR due to a 
posttranslational modification. (A) Average results of NHE-1 activity assessed as 
proton efflux (JH+) during the recovery from intracellular acidosis in isolated 
ventricular myocytes of adult SHR and Wistar rats. These experiments were 
performed in bicarbonate free medium in order to exclude the involvement of any 
other alkalinizing mechanism. (B) No significant difference in myocardial NHE-1 
expression between SHR and Wistar rats was detected by immunoblots. (C) A 
higher phosphorylation of the stimulatory residue serine 703 (downstream target of 
ERK1/2 pathway) was observed in SHR while no difference was evident in the 
inhibitory residue serine 648 (downstream target of AKT) of the NHE-1 regulatory tail 
between rat strains. (D) As expected, a greater activation exclusively of the ERK1/2 
pathway was evident in the SHR myocardium compared to Wistar. Data are express 
as mean ± SEM. Representative immunoblots are shown on top of bars when 
corresponding. The number of experiments (n) is depicted between brackets. * 
indicates P<0.05 vs. Wistar rats (control), t-test.  
Figure 2. IGF-1 exerts an AKT-dependent inhibitory effect on NHE-1 activity in SHR 
cardiomyocytes. (A) Representative recordings of pHi vs. time in the absence 
(control), presence of 10 nmol/L IGF-1, or exposed to 10 nmol/L IGF-1 in 
combination with AG1024 (AG, specific antagonist of IGF-1R), wortmannin (Wort, 
inhibitor of PI3K/AKT) or MK2206 (MK, specific inhibitor of AKT). (B) Average results 
for NHE-1 activity measured as proton efflux (JH+). Comparison among groups was 
done at a common intracellular pH of 6.95, as explained in Methods. It can be 
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appreciated the inhibitory effect of IGF-1 that was cancelled by the different 
pharmacologic inhibitors assayed. * indicates P<0.05 vs. control, ANOVA. (C) IGF-1 
did not modified NHE-1 expression evaluated by quantitative RT-PCR. (D) No 
significant difference was detected in intrinsic buffer capacity (βi) in the presence of 
IGF-1.  The number of experiments (n) is depicted between brackets. * indicates 
P<0.05 vs. control (absence of IGF-1), t-test. 
Figure 3. Signaling pathway activated by IGF-1 in the SHR myocardium. IGF-1 
stimulated the phosphorylation, and therefore activation, of its own receptor (IGF-
1R), AKT, ERK1/2 and p90RSK; being these effects blunted by AG1024, a specific 
antagonist of IGF-1R (Panels A, B, C and D, respectively). (E) In agreement with 
these results, a significant increase in the phosphorylation of the AKT-dependent 
inhibitory site (serine 648) of the cytosolic regulatory domain of the NHE-1 was 
detected. However, no differences at the stimulatory serine 703 site, a specific target 
of ERK1/2-p90RSK pathway, were evident, probably because this site is already 
hyperphosphorylated in the SHR myocardium. Representative immunoblots are 
shown on top and average data ± SEM on bottom of each panel. The number of 
experiments (n) is depicted between brackets. * indicates P<0.05 vs. control 
(absence of IGF-1), ANOVA. 
Figure 4. IGF-1 improves contractility in SHR cardiomyocytes. (A) Representative 
continuous recordings of sarcomere shortening (left) and individual traces before (a) 
and after (b) IGF-1 (right) measured in SHR isolated cardiomyocytes.  (B) Average 
results of the time course of sarcomere shorting for each group. (C) Average values 
of the difference in the relaxation time constant -Tau- at 15 minutes of the 
experimental protocol for each group. AG: AG1024, specific antagonist of IGF-1R; 
MK: MK2206, specific AKT inhibitor. Average data are express as mean ± SEM. The 
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number of experiments (n) is depicted between brackets. * indicates P<0.05 vs. 
control (absence of IGF-1), ANOVA. 
Figure 5. IGF-1 increases calcium transient amplitude and rate of decay in SHR 
isolated cardiomyocytes. (A) Typical tracings showing the effect of IGF-1 on the 
amplitude and decay of the calcium transient. (B) - (C) Overall results for the 
amplitude and time to 50% decay of the calcium transient for each experimental 
group, respectively. (D) Representative Western blots and average results showing 
the effect of IGF-1 on the phosphorylation of CaMKII; threonine 17 (Thr17-PLN, 
target of CaMKII) and serine 16 of phospholamban (Ser16-PLN, target of PKA) in the 
absence and presence of AG1024 (AG). The number of experiments (n) is depicted 
between brackets. * indicates P<0.05 vs. control (absence of IGF-1), ANOVA. 
Figure 6. IGF-1 has an antioxidant effect on the SHR myocardium. (A) Typical 
recordings of DCFDA fluorescence in isolated SHR cardiomyocytes. (B) Average 
results of H2O2 production estimated by the ratio between the slope 2 (after) and 
slope 1 (before) the exposure to IGF-1. (C) Representative measurements and (D) 
average results of myocardial superoxide dismutase (SOD) activity. The experiments 
were performed under control conditions or in the presence of IGF-1 with/without the 
IGF-1R antagonist AG1024 (AG) or the AKT specific inhibitor MK2206. Average data 
are express as mean ± SEM. The number of experiments (n) is depicted between 
brackets. * indicates P<0.05 vs. control (absence of IGF-1), ANOVA. 
Figure 7. Cardioprotective effects of IGF-1 on the SHR myocardium. This cartoon 
schematically summarizes a subcellular explanation for the beneficial effects of IGF-
1, and therefore probably for exercise training, on the hypertrophied heart of the 
SHR. IGF-1 by stimulating its specific receptor (IGF-1R) activates PI3K/AKT 
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signaling that prevents NHE-1 hyperactivity and improves cardiac contractility and 
oxidative stress.   
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